Epratuzumab  (Synonyms: Antibody hLL 2; AMG-412)

Epratuzumab (Antibody hLL 2) is an anti-CD22 IgG1 monoclonal antibody. Epratuzumab is also a tumor-imaging agent and an immunomodulatory agent. Epratuzumab can induce CD22 phosphorylation. Epratuzumab has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases^[1].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

Siglec-2/CD22

Epratuzumab binds to CD22 ECD on Biacore with a K_D of 0.7 nM, and resulting CD22 phosphorylation^[1]. Epratuzumab (0-100 μM; 1h) results in a dose dependent increase in CD22 internalization in Daudi lymphoma cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

933  [NCBI]

P20273

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

146.58 kDa

205923-57-5

Liquid

Colorless to light yellow

[Epratuzumab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized Siglec-2/CD22 Protein, Human can bind Epratuzumab. The EC₅₀ for this effect is 12.52 ng/mL.
• 
  Flow Cytometry analysis of Raji cells labelling Siglec-2/CD22 (red) with Epratuzumab (anti-Siglec-2/CD22) (HY-P99289). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.

• [1]. Carnahan J, et al. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3982S-90S.  [Content Brief]